Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.

Annals of Surgical Oncology
Neal BhutianiRobert C G Martin

Abstract

Previously published work has demonstrated that combining gemcitabine with irreversible electroporation (IRE) results in increased drug delivery to pancreatic adenocarcinoma cells in vivo. This study assessed the efficacy of IRE + gemcitabine and IRE + FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin), the impact of the superior regimen on survival, and the safety of electrochemotherapy in human subjects. Histologic analysis was performed after in vitro and in vivo treatment of S2013 and Panc-1 pancreatic cancer cells and S2013 orthotopic tumors, respectively, and levels of apoptotic machinery and cell cycle proteins were evaluated using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and Western blot. Electrochemotherapy (ECT) with IRE and FOLFIRINOX resulted in increased tumor cells apoptosis compared with gemcitabine, gemcitabine + IRE, and FOLFIRINOX alone, and significantly improved overall survival when compared with mice treated with IRE or FOLFIRINOX. Increased tumor cell apoptosis, caspase-3 mRNA, active caspase-3 protein, and decreased cell proliferation were noted at the time of death or euthanasia in the ECT group compared with folinic acid alone. In five patients, ECT with ...Continue Reading

References

Nov 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y Xu, M A Villalona-Calero
May 2, 2003·Nature Reviews. Cancer·Daniel B LongleyPatrick G Johnston
Dec 9, 2004·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Nicole M ChandlerMark P Callery
Jul 31, 2009·Journal of Biomechanical Engineering·Charlotte Daniels, Boris Rubinsky
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Jun 26, 2012·Journal of the American College of Surgeons·Robert C G MartinVic Velanovich
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Jul 10, 2016·Journal of Surgical Oncology·Neal BhutianiRobert C G Martin
Sep 10, 2016·World Journal of Gastroenterology : WJG·Chiara CaparelloElisa Giovannetti
Sep 28, 2017·Cellular and Molecular Gastroenterology and Hepatology·Kenji IkezawaTetsuo Takehara
Aug 28, 2018·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Alex BarenboimNir Lubezky
Feb 10, 2019·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Michelle M HollandRobert C G Martin

❮ Previous
Next ❯

Citations

Feb 16, 2021·Annals of Surgical Oncology·Rebekah R WhiteRobert C G Martin
Mar 3, 2021·Seminars in Oncology·Wooil KwonMichael D Kluger
May 5, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Kavita MallyaManeesh Jain
May 13, 2021·American Journal of Clinical Oncology·Dimitrios OikonomouEvangelos Felekouras

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Esther Una Cidon, P Alonso
The New England Journal of Medicine
Vanja VaccaroMichele Milella
© 2021 Meta ULC. All rights reserved